Sign in
CompletedPhase 3

Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza

Key facts

Who runs it
Jiaxing AnDiCon Biotech Co.,Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
190 people enrolled
Started
19 Aug 2024
Ended
15 Apr 2025
Type of study
Interventional, 6 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ADC189 tablets
  • Baloxavir Marboxil tablets
  • Placebo of ADC189 tablets
  • Placebo of Baloxavir Marboxil tablets
  • ADC189 granules
  • Placebo of ADC189 granules
  • Placebo of Oseltamivir granules
  • Oseltamivir granules
Record updated
23 September 2025

Who can take part

Age
2 years to 11 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • 1. Patients aged 2 to 11 years at screening, both sex
  • 2. Patients were diagnosed with Influenza A Vairus Infection/Influenza B Virus Infection
  • 3. Parents willing and able to comply with study requirements, under the judgment of investigators
  • 4. Onset of symptoms no more than 48 hours before presentation for screening

Who cannot take part

  • 3. Patients with acute respiratory infection, tympanitis, sinusitis, or acute asthma attack within 2 weeks before screening
  • 5. Other antiviral therapy is required during screening
  • 4. Presence of a chronic disease or illness that may indicate increased risk for influenza-related complications
  • 1. Patients with severe influenza
  • 2. Pregnant or breast-feeding females

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Currently, there is only one treatment which only need one single oral dose for influenza in children five years above (Baloxavir marboxil) in China. This study will test a medicine for influenza in children younger than 5 year of age to see if it is safe and effective.

Read full original descriptionShow less

This is a multicenter, randomized, double-blind, controlled Phase III clinical study.

The study evaluates the pharmacokinetics, safety and efficacy of ADC189 tablets/granules following a single oral dose in children aged 2 to 11 years with influenza.

The 6 groups in the trial

  • ADC189 tablets Group (Part 1)Treatment being tested

    Around 30 patients, 6-11 years old.

    Treatment: ADC189 tablets and Placebo of Baloxavir Marboxil tablets

  • Baloxavir marboxil tablets Group (Part 1)Existing treatment, for comparison

    Around 15 patients, 6-11 years old.

    Treatment: Baloxavir Marboxil tablets and Placebo of ADC189 tablets

  • ADC189 granules Group (Part 2A)Treatment being tested

    Around 60 patients, 5-11 years old.

    Treatment: Placebo of Baloxavir Marboxil tablets and ADC189 granules

  • Baloxavir marboxil tablets (Part 2A)Existing treatment, for comparison

    Around 30 patients, 5-11 years old.

    Treatment: Baloxavir Marboxil tablets and Placebo of ADC189 granules

  • ADC189 granules (Part 2B)Treatment being tested

    Around 20 patients, 2-4 years old.

    Treatment: ADC189 granules and Placebo of Oseltamivir granules

  • Oseltamivir granules (Part 2B)Existing treatment, for comparison

    Around 10 patients, 2-4 years old.

    Treatment: Placebo of ADC189 granules and Oseltamivir granules

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate Pharmacokinetics, Safety and Efficacy of ADC189 Tablets/Granules in Children 2-11 Years Old With Influenza
Record updated
23 September 2025